These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26876431)

  • 1. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
    Moon W; Loftus EV
    Aliment Pharmacol Ther; 2016 Apr; 43(8):863-883. PubMed ID: 26876431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
    Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
    Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of thiopurines in inflammatory bowel disease.
    Derijks LJ; Wong DR
    Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
    Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond.
    Fong SC; Blaker PA; Arenas-Hernandez M; Marinaki AM; Sanderson JD
    Biomark Med; 2015; 9(1):51-65. PubMed ID: 25605455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
    Kakuta Y; Kinouchi Y; Shimosegawa T
    J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Wong DR; Coenen MJ; Derijks LJ; Vermeulen SH; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    Aliment Pharmacol Ther; 2017 Feb; 45(3):391-402. PubMed ID: 27943397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
    Amin J; Huang B; Yoon J; Shih DQ
    Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.